EBioMedicine · 2021
Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Winkler Martin S, Skirecki Tomasz, Brunkhorst Frank M, Cajander Sara, Cavaillon Jean-Marc, Ferrer Ricard, Flohé Stefanie B, García-Salido Alberto, Giamarellos-Bourboulis Evangelos J, Girardis Massimo, Kox Matthijs, Lachmann Gunnar, Martin-Loeches Ignacio, Netea Mihai G, Spinetti Thibaud, Schefold Joerg C, Torres Antoni, Uhle Florian, Venet Fabienne, Weis Sebastian, Scherag André, Rubio Ignacio, Osuchowski Marcin F
Аннотация
Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance and limitations as well as outline their utility in COVID-19 drug and vaccine development. Concurrently, we summarize the status of clinical trial research and discuss the novel tactics utilized in the largest multi-center trials aiming to accelerate generation of reliable results that may subsequently shape COVID-19 clinical treatment practices. We also highlight areas of improvement for animal studies in order to elevate their translational utility. In pandemics, to optimize the use of strained resources in a short time-frame, optimizing and strengthening the synergy between the preclinical and clinical domains is pivotal.